Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5052—Proteins, e.g. albumin
  • A61K9/5057—Gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5089—Processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/01—Hydrocarbons
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
  • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1658—Proteins, e.g. albumin, gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5015—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5169—Proteins, e.g. albumin, gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants

Definitions

• the invention relates to a micro-capsule technology of pigment, in particular to a preparation method of lycopene micro-capsule powder.
• Lycopene is a kind of carotenoids, is one of the strongest antioxidants found in plants in nature, and has important physiological functions. In recent years, epidemiological studies have shown that, compared with other carotenoids, lycopene shows more significant effects in treatment and prevention of a variety of chronic diseases such as tumors, cancers, cardiovascular diseases and arteriosclerosis, and in enhancement of the body immunity. Therefore, the research of lycopene has attracted more and more people's attention.
• Lycopene is a non-cyclic planar polyunsaturated aliphatic hydrocarbon containing eleven conjugated double bonds and two non-conjugated double bonds in its chemical structural formula. Lycopene has strong resistance to oxidation, has unstable properties, and is easily oxidized and degraded by the effects of light, heat and oxygen, which greatly limits application scope thereof. Micro-capsule technology can improve the stability of lycopene by effectively reducing the reaction of active substances to external environmental factors such as light, oxygen and water, thereby increasing application of lycopene in functional products. There are many studies on the application of micro-capsule technology of lycopene in functional nutrition. For example, patent application No.
• CN106038511A proposes a method for preparing nano-sized lycopene micro-encapsulated cold water-dispersed powders, in which a solvent is used to fully dissolve and homogenize lycopene and the compounded nonionic surfactant and the like to obtain nano-sized lycopene micro-capsule powder.
• the lycopene micro-capsule powder prepared by this method has a poor color, and the use of toxic solvents such as ether, petroleum ether, ethyl acetate, acetone, chloroform, and benzene in the preparation process is likely to cause harm to the human body.
• CN104431690A provides a lycopene micro-capsule particle and preparation process thereof, in which vegetable oil is used to disperse lycopene crystals to prepare the oil phase, and the product still exhibits the dark red color of lycopene, which is poor in hue.
• the object of the present invention is to overcome the defects in the prior art, and to provide a preparation method of lycopene micro-capsule powder with good hue and stable properties.
• the method provided by the present invention comprises: fully mixing lycopene with an aqueous phase to obtain a lycopene emulsion; then grinding the emulsion to a particle size of less than 1 ⁇ m, and spray drying.
• the present invention optimizes specific components in the aqueous phase to ensure that lycopene is encapsulated in the wall material composed of the components, thereby having good comprehensive properties.
• the aqueous phase in the present invention comprises enzymatic hydrolysate of gelatin, a disaccharide, a polysaccharide, and an antioxidant.
• Gelatin is a commonly used encapsulating wall material for micro-capsules.
• Commercially available gelatin generally has a large molecular weight of 15000 to 250,000 Da, and dense spatial network structure.
• the product obtained after encapsulating has a dark color tone, a brightness difference of color difference of generally less than 20, and a relatively poor grade.
• enzymatic hydrolysis of gelatin could decrease the molecular weight of gelatin, so as to ensure that the product obtained after encapsulating lycopene with the wall material of the gelatin has good color and luster.
• the gelatin in the gelatin enzymatic hydrolysate has a molecular weight of 5000 to 10000 Da.
• the gelatin enzymatic hydrolysate may be prepared by a method comprising the following steps: adding gelatin to water, and adding protease under conditions of 55 to 65° C. and pH value of 7.5 to 8.5 for enzymatic hydrolysis, after enzymatic hydrolysis is completed, subjecting the resultant to boiling, and then cooling and keeping the temperature at 55 to 65° C. to obtain the gelatin enzymatic hydrolysate.
• the protease may be mercapto protease, preferably papain.
• the mass ratio of gelatin to water is (1-2):(3-4), and the dosage of the protease is 2.0% to 3.0% of the mass of gelatin.
• the disaccharide is selected from sucrose, maltose and/or lactose, and the polysaccharide is pullulan polysaccharide and/or chitosan.
• the use of the above-mentioned preferred sugar components can ensure the synergistic effect thereof with the gelatin enzymatic hydrolysate so as to form a denser network structure for encapsulating lycopene, so that the lycopene micro-capsule powder has good color and luster and stability.
• the antioxidant in the present invention is used to prevent lycopene from oxidative inactivation. It is sufficient to use food-grade natural antioxidants commonly used in the art, such as one or a mixture of ascorbic acid and vitamin E.
• the amount of each component is optimized in the present invention.
• the aqueous phase comprises: gelatin enzymatic hydrolysate with a molecular weight 5000 to 10000 Da obtained from 1 to 2 parts of gelatin and 3 to 4 parts of water as raw materials through enzymatic hydrolysis, 2 to 3 parts of disaccharide, 0.3 to 0.5 parts of polysaccharide, and 0.1 to 0.2 parts of antioxidant.
• the aqueous phase can be fully stirred at 55 to 65° C., for example, at a rotation speed of 30 to 50 r/min for 30 to 60 min to ensure that the components are fully mixed to obtain homologous aqueous phase.
• the lycopene and the aqueous phase are preferably mixed in a specific ratio, and in terms of the gelatin in the aqueous phase, the mass ratio of the lycopene to gelatin is preferably 1:(1-2).
• the lycopene and the aqueous phase are fully mixed, preferably sheared and stirred at 7000 to 9000 r/min at 55 to 65° C. to obtain a lycopene emulsion with an excellent mixing degree.
• the raw material of lycopene used is preferably lycopene crystals.
• the grinding comprises grinding to a particle size of 200 to 600 nm in order to obtain a product with good performance and using effect.
• the grinding can be carried out by a nano-grinder to obtain a desired particle size.
• the grinding is carried out at a rotation speed of 1600 to 1800 r/min for 1.0 to 2.0 h.
• the spray drying is carried out by conventional spray drying methods in the art.
• the following parameters may be used: an inlet air temperature of 165 to 180° C., an outlet air temperature of 90 to 105° C., and an air rate of 300 to 500 mL/h.
• the method for preparing the lycopene micro-capsule powder comprises the following specific steps:
• gelatin enzymatic hydrolysate with a molecular weight of 5000 to 10000 Da at a temperature of 55 to 65° C.
• the invention also claims the lycopene micro-capsule powder prepared by the above-mentioned method.
• the color values of the lycopene micro-capsule powder provided by the present invention could be: L*38.5 to 40.5; a*29.0 to 30.0; b*19.0 to 20.0. After long-term storage, the lycopene content and color values remain stable.
• a lycopene micro-capsule powder is obtained by using enzymatically-hydrolyzed gelatin as a wall material, combining the grinding effect of a nano-grinder, and using spray drying, which solves the problems of dark color luster and poor stability to light, heat and free radical.
• the color tone of the obtained lycopene micro-capsule powder is cherry red, which is brighter and more vivid, and could improve the appetite of consumers.
• the obtained lycopene micro-capsule powder has high stability to light, heat and free radicals.
• the method provided by the invention is simple, environmentally friendly, low in production cost, and suitable for large-scale preparation of lycopene micro-capsule powder.
• the present Example provides a preparation method of lycopene micro-capsule powder, specifically comprising the following steps:
• the lycopene emulsion was ground by a nano-grinder at a rotation speed of 1700 r/min for 1.5 h to obtain a lycopene microemulsion with a particle size of 400 nm;
• the lycopene microemulsion was spray-dried with an inlet air temperature of 175° C., an outlet air temperature of 100° C., and a flow rate of 500 mL/h to obtain a lycopene micro-capsule powder.
• the present Example provides a preparation method of lycopene micro-capsule powder, specifically comprising the following steps:
• gelatin was added to 437.5 g of purified water, and papain was added in an amount of 6 g.
• the resulting solution was adjusted to a pH of 8.0, and subjected to enzymatic hydrolysis at a temperature of 60° C. in water bath for 5 h.
• the resultant was boiled for 15 min, and then cooled to 60° C. to obtain a gelatin enzymatic hydrolysate.
• the gelatin in the gelatin enzymatic hydrolysate had a molecular weight of 8000 Da;
• the lycopene emulsion was ground by a nano-grinder at a rotation speed of 1800 r/min for 1 h to obtain a lycopene microemulsion with a particle size of 500 nm;
• the lycopene microemulsion was spray-dried with an inlet air temperature of 180° C., an outlet air temperature of 105° C., and a flow rate of 400 mL/h to obtain a lycopene micro-capsule powder.
• the present Example provides a preparation method of lycopene micro-capsule powder, specifically comprising the following steps:
• gelatin 165 g was added to 440 g of purified water, and papain was added in an amount of 3.3 g.
• the resulting solution was adjusted to a pH of 8.5, and subjected to enzymatic hydrolysis at a temperature of 65° C. in water bath for 4 h.
• the resultant was boiled for 15 min, and then cooled to 65° C. to obtain a gelatin enzymatic hydrolysate.
• the gelatin in the gelatin enzymatic hydrolysate had a molecular weight of 5000 Da;
• the lycopene emulsion was ground by a nano-grinder at a rotation speed of 1800 r/min for 2.0 h to obtain a lycopene microemulsion with a particle size of 200 nm;
• the lycopene microemulsion was spray-dried with an inlet air temperature of 170° C., an outlet air temperature of 95° C., and a flow rate of 300 mL/h to obtain a lycopene micro-capsule powder.
• the present Example provides a preparation method of lycopene micro-capsule powder, specifically comprising the following steps:
• gelatin 100 g was added to 320 g of purified water, and papain was added in an amount of 2.5 g.
• the resulting solution was adjusted to a pH of 8.2, and subjected to enzymatic hydrolysis at a temperature of 60° C. in water bath for 3.5 h.
• the resultant was boiled for 15 min, and then cooled to 55° C. to obtain a gelatin enzymatic hydrolysate.
• the gelatin in the gelatin enzymatic hydrolysate had a molecular weight of 10000 Da;
• the lycopene emulsion was ground by a nano-grinder at a rotation speed of 1600 r/min for 1.0 h to obtain a lycopene microemulsion with a particle size of 600 nm;
• the lycopene microemulsion was spray-dried with an inlet air temperature of 165° C., an outlet air temperature of 90° C., and a flow rate of 450 mL/h to obtain a lycopene micro-capsule powder.
• the lycopene emulsion was ground by a nano-grinder at a rotation speed of 1700 r/min for 1.5 h to obtain a lycopene microemulsion with a particle size of 1.2 ⁇ m;
• the lycopene microemulsion was spray-dried with an inlet air temperature of 175° C., an outlet air temperature of 100° C., and a flow rate of 500 mL/h to obtain a lycopene micro-capsule powder.
• the method provided by the present invention can effectively improve the color tone of the obtained product compared with the dark red color of other products, making it brighter and more vivid.
• the lycopene micro-capsule powders provided in Examples 1 to 4 were kept at a temperature of 25° C. and a humidity of 60% in dark for one year. The content of lycopene and chroma were tested. The test results were shown in Table 2.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Immunology (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Inorganic Chemistry (AREA)
• Toxicology (AREA)
• Botany (AREA)
• Mycology (AREA)
• Nutrition Science (AREA)
• Medicinal Preparation (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Manufacturing Of Micro-Capsules (AREA)

Applications Claiming Priority (1)

Related Parent Applications (1)

Publications (2)

Family

ID=66750750

Family Applications (1)

Country Status (9)

Families Citing this family (5)

Citations (10)

Family Cites Families (12)

• 2017
  • 2017-12-08 EP EP17934086.4A patent/EP3721874B1/en active Active
  • 2017-12-08 DK DK17934086.4T patent/DK3721874T3/da active
  • 2017-12-08 JP JP2020549844A patent/JP6955113B2/ja active Active
  • 2017-12-08 KR KR1020207016668A patent/KR102422516B1/ko active IP Right Grant
  • 2017-12-08 WO PCT/CN2017/115271 patent/WO2019109346A1/zh unknown
  • 2017-12-08 ES ES17934086T patent/ES2920153T3/es active Active
  • 2017-12-08 CN CN201780097555.4A patent/CN111447925B/zh active Active
• 2020
  • 2020-06-02 IL IL275072A patent/IL275072B/en unknown
  • 2020-06-08 US US16/896,011 patent/US11723879B2/en active Active

Patent Citations (10)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events